27 April 2008

Sunday Herald Sun - Stem Cell Hope for Fixing Injured Knees

A WORLD-FIRST trial to be conducted in Melbourne could revolutionise the treatment of chronic knee injuries using adult stem cells.

Up to 60 Victorians are to trial a simple injection scientists believe could replace drugs - and even surgery- in treating debilitating osteoarthritis.

It could also prolong the careers of athletes, including AFL players, regularly sidelined by common cartilage tears.

Melbourne-based biotechnology company Mesoblast recently completed successful animal trials of the hi-tech procedure and believe there is a "billion-dollar market" for their technique.

The Australian trials found the injection of adult stem cells - taken from human donors' bone marrow, abdominal fat, hip, skin or teeth - protected damaged knee cartilage for up to nine months.

Professor Silviu Itescu, Mesoblast's director and chief scientific adviser, said the injected stem cells bound themselves to the cartilage, halting its degen eration.

"Is it that the cells are protecting the cartilage, or is it accelerating the rate of repair? At the moment, we don't know," he said. "Either way, the result is more cartilage, thicker cartilage."

Leading sports physician Dr Peter Larkins said stem cell therapy had the potential to prolong athletes' careers. "In terms of medical break throughs, it's a sensational prospect, if it works," he said.

The human trials, to be conducted in Melbourne and in the US, will involve about 80 pa tients aged 45-55 who have had knee arthroscopes in the pre vious month.

That is the surgery track star Jana Rawlinson famously underwent to compete in the 2004 Athens Olympics. Dr Peter Ghosh, Mesoblast's chief cartilage scientist, said the weeks after arthroscopic surgery - which typically involves the removal of a cartilage called meniscus - was the ideal time to test the injection of cells.

"As you get older, (meniscus) degenerates but, more commonly in younger people, it is also torn. It is a very common injury for football and netball players," he said.

"When it's torn, it can lock the joint and give you pain and symptoms and the joint blows up. It has to be removed."

However Dr Ghosh said the surgery, known as a meniscectomy, often fast-tracks the development of osteoarthritis, the degeneration of joint cartilage that affects about 1.3 million Australians.

"So football players and men and women in the street who have had this operation live in fear that when they reach 50 or 60, they'll be faced with this debilitating disorder."

If the trials are successful, Dr Ghosh said the "off-the-shelf' product would be on the market by 2012 and could treat "any joint that can be injected".

 

 

>>back to What They Say

 

 

Last Share Price

August 26 2010- Preliminary 2010 Annual Report

August 26 2010 - Mesoblast Financial Year End Results; Strong Clinical Progress, Major Regulatory Milestone and Enhanced Corporate Strategy

23 August 2010 - EGM documents - Letter from the Chairman, Notice of Meeting, Independent Expert Report.

16 August - Mesoblast on track for phase 3 bone marrow transplant trial following positive meeting with FDA

21 July - Mesoblast receives TGA regulatory approval to commercially manufacture adult stem cell products

12 July - Phase 3 meeting scheduled with FDA following positive results of bone marrow regeneration trial

28 May - Mesoblast featured at ASX Singapore conference highlighting emerging market leaders

19 May - United States FDA Clears Phase 2 Trial for Cervical Spinal Fusion

16 August 2010 - Southern Cross Equities research - Phase III getting ready for takeoff

23 July 2010 - Southern Cross Equities Research – Big Pharma will be watching

21 July 2010 - Southern Cross Equities Research – The clinical endgame nears

17 May 2010 - Southern Cross Equities Research – Capitalising the Stem Cell Opportunity

14 May 2010 - Bioshares

26 February - RBS Equities Research - Mesoblast (Buy) 1H10 - Master Blasters

July 2009 - Chairman’s Letter

May 2009 - Chairman’s Letter

May 2008 - Issue Nine